The purpose of this study is to better understand how young adults (ages 18 - 39) who have had cancer use entertainment media during and after cancer treatment.
African American communities have been disproportionately affected by the burdens of cancer, yet their experiences and voices remain underrepresented in health research. In this study, we want to understand the experiences and perspectives of African American/Black individuals who support or care for their loved ones diagnosed with cancer.
This is a registry of childhood, adolescent, and young adult patients with cancer. This registry is for anyone diagnosed with cancer before the age of 40 years to establish a UNC-based resource for the prospective study of the long-term, treatment-related effects, particularly the early aging effects, of cancer and its treatment.
To evaluate whether early drug treatment extends overall survival compared with delayed drug treatment with high-risk (chronic lymphocytic leukemia [CLL] newly diagnosed asymptomatic CLL/SLL patients.
Immune checkpoint inhibitors (ICIs) are a type of cancer treatment that work by over-activating the immune system to find and kill cancer cells. This type of treatment can sometimes lead to side effects that look like autoimmune diseases (diseases where the immune system attacks the body). We want to collects samples and clinical data from cancer patients taking ICI therapy to understand why some patients get side effects and others don't.
Do you have mantle cell lymphoma or other non-Hodgkin lymphoma that has either come back or did not get better with your last treatment? If so, you may be able to take part in a study that will modify your own immune cells to see if it may treat your cancer.
Have you been diagnosed with primary central nervous system (CNS) lymphoma? If so you may be able to take part in a research study looking at whether using the study drugs lenalidomide, and nivolumab can be safely used in addition to the standard treatment of primary CNS lymphoma, and which dose is the most adequate when they are used together.
The purpose of this study is to test whether giving the study drug acalabrutinib is safe and could help control B-cell Non-Hodgkin CNS lymphoma that have not gone away, or have come back, after the first round of treatment.
The purpose of this research study is to deliver 6 months of 1:1 health coaching to cancer patients being treated at UNC Cancer Hospital. This program hopes to improve patient's self-confidence and satisfaction with how they feel and what they are able to do day-to-day. This includes exercising, support for healthy eating, emotional and social needs. Health coaching means you will receive weekly phone calls and emails from a trained coach.
Do you have Peripheral T Cell Lymphoma? Has your cancer come back or did it not get better with the last treatment you were given? If so, you may be eligible to participate in this gene therapy research study to learn more about using your own modified immune cells as possible treatment.